Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms

Molecular Cell

Volumn 42, Issue 1, 2011, Pages 9-22

  Jura, Natalia ^a,b   Zhang, Xuewu ^d   Endres, Nicholas F ^a,b   Seeliger, Markus A ^e   Schindler, Thomas ^f   Kuriyan, John ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e STONY BROOK UNIVERSITY   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; LEUCINE; LYSINE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE P60; THREONINE; TYROSINE;

ALLOSTERISM; ALPHA HELIX; AMINO TERMINAL SEQUENCE; CATALYSIS; CRYSTAL STRUCTURE; ENZYME ACTIVATION; ENZYME REGULATION; HELIX (SNAIL); INTRACELLULAR SIGNALING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ALLOSTERIC REGULATION; CATALYSIS; CYCLIN-DEPENDENT KINASES; DIMERIZATION; ENZYME ACTIVATION; ENZYME STABILITY; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN KINASES; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES;

EID: 79953308071     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2011.03.004     Document Type: Review

References (104)

1. Aifa S., Aydin J., Nordvall G., Lundstrom I., Svensson S.P., Hermanson O. A basic peptide within the juxtamembrane region is required for EGF receptor dimerization. Exp. Cell Res. 2005, 302:108-114.
2. Azam M., Seeliger M.A., Gray N.S., Kuriyan J., Daley G.Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 2008, 15:1109-1118.
3. Bargmann C.I., Hung M.C., Weinberg R.A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986, 45:649-657.
4. Bargmann C.I., Hung M.C., Weinberg R.A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986, 319:226-230.
5. Bayliss R., Sardon T., Vernos I., Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. Cell 2003, 12:851-862.
6. Biondi R.M., Cheung P.C., Casamayor A., Deak M., Currie R.A., Alessi D.R. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J. 2000, 19:979-988.
7. Biondi R.M., Komander D., Thomas C.C., Lizcano J.M., Deak M., Alessi D.R., van Aalten D.M. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J. 2002, 21:4219-4228.
8. Biscardi J.S., Maa M.C., Tice D.A., Cox M.E., Leu T.H., Parsons S.J. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 1999, 274:8335-8343.
9. Bocharov E.V., Mineev K.S., Volynsky P.E., Ermolyuk Y.S., Tkach E.N., Sobol A.G., Chupin V.V., Kirpichnikov M.P., Efremov R.G., Arseniev A.S. Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state. J. Biol. Chem. 2008, 283:6950-6956.
10. Bossemeyer D., Engh R.A., Kinzel V., Ponstingl H., Huber R. Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J. 1993, 12:849-859.
11. Bublil E.M., Pines G., Patel G., Fruhwirth G., Ng T., Yarden Y. Kinase-mediated quasi-dimers of EGFR. FASEB J. 2010, 24:4744-4755.
12. Carpenter G., Lembach K.J., Morrison M.M., Cohen S. Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. J. Biol. Chem. 1975, 250:4297-4304.
13. Chen L., Merzlyakov M., Cohen T., Shai Y., Hristova K. Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers. Biophys. J. 2009, 96:4622-4630.
14. Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., Seeburg P.H., Libermann T.A., Schlessinger J., Francke U., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230:1132-1139.
15. Day P.J., Cleasby A., Tickle I.J., O'Reilly M., Coyle J.E., Holding F.P., McMenamin R.L., Yon J., Chopra R., Lengauer C., et al. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc. Natl. Acad. Sci. USA 2009, 106:4166-4170.
16. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., Kim S.H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363:595-602.
17. Deindl S., Kadlecek T.A., Brdicka T., Cao X., Weiss A., Kuriyan J. Structural basis for the inhibition of tyrosine kinase activity of ZAP-70. Cell 2007, 129:735-746.
18. Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P., Ullrich A., Schlessinger J., Waterfield M.D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984, 307:521-527.
19. Duneau J.P., Vegh A.P., Sturgis J.N. A dimerization hierarchy in the transmembrane domains of the HER receptor family. Biochemistry 2007, 46:2010-2019.
20. Engel M., Hindie V., Lopez-Garcia L.A., Stroba A., Schaeffer F., Adrian I., Imig J., Idrissova L., Nastainczyk W., Zeuzem S., et al. Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. EMBO J. 2006, 25:5469-5480.
21. Eswaran J., Knapp S. Insights into protein kinase regulation and inhibition by large scale structural comparison. Biochim. Biophys. Acta 2010, 1804:429-432.
22. Filippakopoulos P., Kofler M., Hantschel O., Gish G.D., Grebien F., Salah E., Neudecker P., Kay L.E., Turk B.E., Superti-Furga G., et al. Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 2008, 134:793-803.
23. Gonfloni S., Weijland A., Kretzschmar J., Superti-Furga G. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat. Struct. Biol. 2000, 7:281-286.
24. Gotoh N., Tojo A., Hino M., Yazaki Y., Shibuya M. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 1992, 186:768-774.
25. Grant B.D., Adams J.A. Pre-steady-state kinetic analysis of cAMP-dependent protein kinase using rapid quench flow techniques. Biochemistry 1996, 35:2022-2029.
26. Grodsky N., Li Y., Bouzida D., Love R., Jensen J., Nodes B., Nonomiya J., Grant S. Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor. Biochemistry 2006, 45:13970-13981.
27. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., Carraway K.L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 1994, 91:8132-8136.
28. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241:42-52.
29. Hindie V., Stroba A., Zhang H., Lopez-Garcia L.A., Idrissova L., Zeuzem S., Hirschberg D., Schaeffer F., Jorgensen T.J., Engel M., et al. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat. Chem. Biol. 2009, 5:758-764.
30. Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 1997, 16:5572-5581.
31. Hubbard S.R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2004, 5:464-471.
32. Hubbard S.R., Till J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 2000, 69:373-398.
33. Hubbard S.R., Miller W.T. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr. Opin. Cell Biol. 2007, 19:117-123.
34. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell 2002, 109:275-282.
35. Jeffrey P.D., Russo A.A., Polyak K., Gibbs E., Hurwitz J., Massague J., Pavletich N.P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995, 376:313-320.
36. Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H., Wemmer D.E., Zhang X., Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009, 137:1293-1307.
37. Jura N., Shan Y., Cao X., Shaw D.E., Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. USA 2009, 106:21608-21613.
38. Khazaie K., Dull T.J., Graf T., Schlessinger J., Ullrich A., Beug H., Vennstrom B. Truncation of the human EGF receptor leads to differential transforming potentials in primary avian fibroblasts and erythroblasts. EMBO J. 1988, 7:3061-3071.
39. Knighton D.R., Zheng J.H., Ten Eyck L.F., Ashford V.A., Xuong N.H., Taylor S.S., Sowadski J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991, 253:407-414.
40. Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S., Santoro M., Ibanez C.F., McDonald N.Q. Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 2006, 281:33577-33587.
41. Kornev A.P., Taylor S.S. Defining the conserved internal architecture of a protein kinase. Biochim. Biophys. Acta 2010, 1804:440-444.
42. Kornev A.P., Haste N.M., Taylor S.S., Eyck L.F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. USA 2006, 103:17783-17788.
43. Kornev A.P., Taylor S.S., Ten Eyck L.F. A helix scaffold for the assembly of active protein kinases. Proc. Natl. Acad. Sci. USA 2008, 105:14377-14382.
44. Lei M., Robinson M.A., Harrison S.C. The active conformation of the PAK1 kinase domain. Structure 2005, 13:769-778.
45. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
46. Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M., Karplus M., Cole P.A., Kuriyan J. A Src-like inactive conformation in the Abl tyrosine kinase domain. PLoS Biol. 2006, 4:e144. 10.1371/journal.pbio.0040144.
47. Levinson N.M., Seeliger M.A., Cole P.A., Kuriyan J. Structural basis for the recognition of c-Src by its inactivator Csk. Cell 2008, 134:124-134.
48. Lew J., Taylor S.S., Adams J.A. Identification of a partially rate-determining step in the catalytic mechanism of cAMP-dependent protein kinase: a transient kinetic study using stopped-flow fluorescence spectroscopy. Biochemistry 1997, 36:6717-6724.
49. Lochhead P.A., Sibbet G., Morrice N., Cleghon V. Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs. Cell 2005, 121:925-936.
50. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
51. Macdonald-Obermann J.L., Pike L.J. The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding. J. Biol. Chem. 2009, 284:13570-13576.
52. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
53. Martin G.S. The road to Src. Oncogene 2004, 23:7910-7917.
54. Mendrola J.M., Berger M.B., King M.C., Lemmon M.A. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J. Biol. Chem. 2002, 277:4704-4712.
55. Min X., Lee B.H., Cobb M.H., Goldsmith E.J. Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure 2004, 12:1303-1311.
56. Mineev K.S., Bocharov E.V., Pustovalova Y.E., Bocharova O.V., Chupin V.V., Arseniev A.S. Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. J. Mol. Biol. 2010, 400:231-243.
57. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., Snell G.P., Zou H., Sang B.C., Wilson K.P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 2004, 279:31655-31663.
58. Monsey J., Shen W., Schlesinger P., Bose R. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J. Biol. Chem. 2010, 285:7035-7044.
59. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002, 62:4236-4243.
60. Nagar B., Hantschel O., Seeliger M., Davies J.M., Weis W.I., Superti-Furga G., Kuriyan J. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol. Cell 2006, 21:787-798.
61. Noble M.E., Endicott J.A., Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303:1800-1805.
62. Nolen B., Taylor S., Ghosh G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 2004, 15:661-675.
63. Padyana A.K., Qiu H., Roll-Mecak A., Hinnebusch A.G., Burley S.K. Structural basis for autoinhibition and mutational activation of eukaryotic initiation factor 2alpha protein kinase GCN2. J. Biol. Chem. 2005, 280:29289-29299.
64. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
65. Pawson T., Kofler M. Kinome signaling through regulated protein-protein interactions in normal and cancer cells. Curr. Opin. Cell Biol. 2009, 21:147-153.
66. Pearce L.R., Komander D., Alessi D.R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 2010, 11:9-22.
67. Pines G., Huang P.H., Zwang Y., White F.M., Yarden Y. EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene 2010, 29:5850-5860.
68. Prigent S.A., Gullick W.J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 1994, 13:2831-2841.
69. Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S., Pal A., Bornmann W.G., Lemmon M.A., Cole P.A., et al. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 2008, 16:460-467.
70. Red Brewer M., Choi S.H., Alvarado D., Moravcevic K., Pozzi A., Lemmon M.A., Carpenter G. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol. Cell 2009, 34:641-651.
71. Rellos P., Ivins F.J., Baxter J.E., Pike A., Nott T.J., Parkinson D.M., Das S., Howell S., Fedorov O., Shen Q.Y., et al. Structure and regulation of the human Nek2 centrosomal kinase. J. Biol. Chem. 2007, 282:6833-6842.
72. Robinson M.J., Harkins P.C., Zhang J., Baer R., Haycock J.W., Cobb M.H., Goldsmith E.J. Mutation of position 52 in ERK2 creates a nonproductive binding mode for adenosine 5′-triphosphate. Biochemistry 1996, 35:5641-5646.
73. Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 1999, 3:639-648.
74. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289:1938-1942.
75. Seeliger M.A., Ranjitkar P., Kasap C., Shan Y., Shaw D.E., Shah N.P., Kuriyan J., Maly D.J. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 2009, 69:2384-2392.
76. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., Moasser M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
77. Shan Y., Seeliger M.A., Eastwood M.P., Frank F., Xu H., Jensen M.O., Dror R.O., Kuriyan J., Shaw D.E. A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc. Natl. Acad. Sci. USA 2009, 106:139-144.
78. Shi F., Telesco S.E., Liu Y., Radhakrishnan R., Lemmon M.A. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA 2010, 107:7692-7697.
79. Sicheri F., Moarefi I., Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997, 385:602-609.
80. Sierke S.L., Cheng K., Kim H.H., Koland J.G. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem. J. 1997, 322:757-763.
81. Spector N.L., Xia W., Burris H., Hurwitz H., Dees E.C., Dowlati A., O'Neil B., Overmoyer B., Marcom P.K., Blackwell K.L., et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 2005, 23:2502-2512.
82. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277:46265-46272.
83. Takaki T., Echalier A., Brown N.R., Hunt T., Endicott J.A., Noble M.E. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc. Natl. Acad. Sci. USA 2009, 106:4171-4176.
84. Thiel K.W., Carpenter G. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc. Natl. Acad. Sci. USA 2007, 104:19238-19243.
85. Tice D.A., Biscardi J.S., Nickles A.L., Parsons S.J. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 1999, 96:1415-1420.
86. Tokarski J.S., Newitt J.A., Chang C.Y., Cheng J.D., Wittekind M., Kiefer S.E., Kish K., Lee F.Y., Borzillerri R., Lombardo L.J., et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006, 66:5790-5797.
87. Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., Lee J., Yarden Y., Libermann T.A., Schlessinger J., et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309:418-425.
88. Wallasch C., Weiss F.U., Niederfellner G., Jallal B., Issing W., Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995, 14:4267-4275.
89. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., Goldsmith E.J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6:1117-1128.
90. Wang W., Marimuthu A., Tsai J., Kumar A., Krupka H.I., Zhang C., Powell B., Suzuki Y., Nguyen H., Tabrizizad M., et al. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc. Natl. Acad. Sci. USA 2006, 103:3563-3568.
91. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64:6652-6659.
92. Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L., Caferro T.R., Dickerson S.H., Dickson H.D., Donaldson K.H., Gaul M., et al. 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases. Proc. Natl. Acad. Sci. USA 2008, 105:2773-2778.
93. Xu W., Harrison S.C., Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997, 385:595-602.
94. Xu W., Doshi A., Lei M., Eck M.J., Harrison S.C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 1999, 3:629-638.
95. Yamaguchi H., Hendrickson W.A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996, 384:484-489.
96. Yamaguchi H., Kasa M., Amano M., Kaibuchi K., Hakoshima T. Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. Structure 2006, 14:589-600.
97. Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., Saito T., Toyoshima K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986, 319:230-234.
98. Yang J., Cron P., Thompson V., Good V.M., Hess D., Hemmings B.A., Barford D. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell 2002, 9:1227-1240.
99. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
100. Yun C.H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M., Eck M.J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11:217-227.
101. Zhang F., Strand A., Robbins D., Cobb M.H., Goldsmith E.J. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature 1994, 367:704-711.
102. Zhang X., Gureasko J., Shen K., Cole P.A., Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137-1149.
103. Zhang X., Pickin K.A., Bose R., Jura N., Cole P.A., Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007, 450:741-744.
104. Zheng J., Knighton D.R., ten Eyck L.F., Karlsson R., Xuong N., Taylor S.S., Sowadski J.M. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 1993, 32:2154-2161.